Pumitepa

This classification denotes an antineoplastic alkylating agent with the molecular formula C12H19N8OP, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7AYY495RE0, chemically known as p,p-bis(1-aziridinyl)-n-(2-(dimethylamino)-7-methylpurin-6-yl)phosphinic amide but more generally known as pumitepa, which bears US NIH Compound Identifier 68669. European Medicines Agency schedules Pumitepa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10160MIG. The term PUMITEPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). PUMITEPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pumitepa under HS 29335995 and SITC 51576. As of Q4 2014, PUMITEPA remains US FDA's Preferred Term for this commodity. Pumitepa bears US NLM identifiers UMLS ID C0060632 and NCI Concept Code C73239. SMILES: CN1C=NC2=C1C(=NC(=N2)N(C)C)NP(=O)(N3CC3)N4CC4.